Patents by Inventor Marc Vandermeeren

Marc Vandermeeren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
    Patent number: 11673943
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 13, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Antibodies to Pyroglutamate Amyloid-β and Uses Thereof
    Publication number: 20210147528
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Methods of detecting pyroglutamate amyloid beta protein (3pE A?) using anti-3pE A? antibodies
    Patent number: 10851156
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: December 1, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
    Publication number: 20200165328
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 28, 2020
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Antibodies to pyroglutamate amyloid-? and uses thereof
    Patent number: 10519223
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: December 31, 2019
    Assignee: Jannsen Pharmaceutica NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Anti-PHG-tau antibodies and their uses
    Patent number: 10196440
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 5, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • ANTI-PHF-TAU ANTIBODIES AND THEIR USES
    Publication number: 20180305445
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: May 21, 2018
    Publication date: October 25, 2018
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Anti-PHF-tau antibodies and their uses
    Patent number: 10000559
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: June 19, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
    Publication number: 20180142011
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 24, 2018
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Anti-PHF-tau Antibodies and Their Uses
    Publication number: 20170355758
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: July 11, 2017
    Publication date: December 14, 2017
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Anti-PHF-tau antibodies and their uses
    Patent number: 9745371
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 29, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Anti-PHF-tau Antibodies and Their Uses
    Publication number: 20160304593
    Abstract: The present invention relates to anti- PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: April 26, 2016
    Publication date: October 20, 2016
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Anti-PHF-tau antibodies and their uses
    Patent number: 9371376
    Abstract: Anti-PHF-tau antibodies and methods of making and using them are disclosed.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 21, 2016
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xueson Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • ANTI-PHF-TAU ANTIBODIES AND THEIR USES
    Publication number: 20150307600
    Abstract: Anti-PHF-tau antibodies and methods of making and using them are disclosed.
    Type: Application
    Filed: December 19, 2012
    Publication date: October 29, 2015
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xueson Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Isolated microtubule-associated protein tau peptides and kit
    Patent number: 8163873
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: April 24, 2012
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
  • Isolsted Monoclonal - Associated Protein Tau and Kit
    Publication number: 20110143443
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 16, 2011
    Applicant: N.V. Innogenetics S. A.
    Inventors: Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
  • Monoclonal Antibodies Directed Against The Microtubule-Associated Protein Tau
    Publication number: 20090137051
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Application
    Filed: November 10, 2008
    Publication date: May 28, 2009
    Applicant: N.V. Innogenetics S. A.
    Inventors: Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
  • N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
    Publication number: 20060127954
    Abstract: This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A?11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
    Type: Application
    Filed: September 9, 2003
    Publication date: June 15, 2006
    Inventors: Marc Mercken, Marc Vandermeeren
  • Monoclonal antibodies directed against the microtubule-associated protein tau and method of detecting the same
    Publication number: 20060008853
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itslf isolated from the cerebral cortex of a patient having Alzheimer's disease. Further, a method of detecting the tau protein is claimed.
    Type: Application
    Filed: August 20, 2004
    Publication date: January 12, 2006
    Applicant: N.V. Innogenetics S.A.
    Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Van De Voorde
  • Monoclonal antibodies directed against the microtubule-associated protein tau
    Patent number: 6900293
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: May 31, 2005
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, André Van De Voorde